Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Multi-cohort Clinical Study to Explore the Preliminary Efficacy and Safety of Zanidatamab in Combination With Tislelizumab for HER2-Positive GI Tumors: the UNION-HER2-BASKET Study

NCT07243938 is registered in ClinicalTrials.gov with Tao Zhang as lead sponsor.

NCT NCT07243938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07243938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Multi-cohort Clinical Study to Explore the Preliminary Efficacy and Safety of Zanidatamab in Combination With Tislelizumab for HER2-Positive GI Tumors: the UNION-HER2-BASKET Study
Lead sponsor
Tao Zhang
Phase
Phase 2
Overall status
Not yet recruiting
Start date
January 15, 2026
Completion date
June 1, 2031
Enrollment
70 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

locally advanced gastric/gastroesophageal junction adenocarcinoma, locally advanced rectal cancer (larc), metastatic colorectal cancer (mcrc), neoadjuvant therapy